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Health-Related Quality of Life (HRQoL). To inform the design of a large-scale pro-
spective study of the patient-reported impact of HZ and PHN in the UK, a review of 
published prospective studies was conducted. METHODS: A targeted literature review 
was conducted in MEDLINE® to identify prospective studies investigating the impact 
of HZ and PHN from the patient’s perspective. Searches were limited to studies 
published in English between April 2000 and April 2010. The adequacy of these 
studies in quantifying the burden of HZ and PHN was critically assessed. RESULTS: 
Only a small number of published prospective studies (n = 6) designed to investigate 
the impact of HZ or PHN from patients’ perspectives were identiﬁ ed; one of which 
was conducted in the UK. The HRQoL burden associated with HZ and PHN was 
highlighted in the studies reviewed albeit a number of key points were noted. First, 
the burden of HZ and PHN has not been compared to HRQoL estimates for the 
general population or to those with comparable acute or chronic conditions, thereby 
making interpretation difﬁ cult. Furthermore, studies conducted to date have not 
accounted for the variations in pain and HRQOL burden at different stages of HZ 
presentation. Finally, from the studies reviewed, the pain experienced by patients with 
HZ and PHN is managed with a wide variety of products. However, until now no 
formal assessment of patient satisfaction with these products has been conducted. 
CONCLUSIONS: Although it is known that HZ and PHN can have a negative impact 
on HRQOL, limitations in previous research can be noted. In order to address these 
concerns, a large-scale UK-based prospective study is currently being conducted.
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OBJECTIVES: Incidence and severity of herpes zoster (HZ) increase with age. Posther-
petic neuralgia (PHN) is its most common complication. The study objective was to 
assess the impact of HZ and PHN on daily life and quality of life (QoL) as perceived 
by the patient. METHODS: A 12-month, longitudinal, observational study conducted 
on patients aged ≥50 years with acute HZ (eruptive phase), included by a representa-
tive sample of 644 French general practitioners (GP) between June 2007 and June 
2008. Demographic and disease characteristics and treatment procedures were col-
lected by the GP at the inclusion and at 3, 6 and 12 months. PHN and QoL assess-
ments were performed by telephone interview of patients, at regular time points over 
12 months, using comprehensive and validated questionnaires. RESULTS: a total of 
1358 patients met the selection criteria and 1032 completed the follow-up. Mean age 
was 67.7 ± 10.7 years (62.2% female). Mean time between rash onset and HZ diag-
nosis was 2.6 ± 3.0 days. Most patients (94.1%) were treated with antiviral drugs. 
PHN prevalence at inclusion, 3, 6, and 12 months was 79.6%, 11.6%, 8.5%, and 
6.6% respectively. Mean Zoster Brief Pain Inventory (ZBPI) interference score (range 
= 0–10 worse) at inclusion, 3, 6 and 12 months was 3.1 ± 2.4, 2.9 ± 2.3, 2.5 ± 2.1, 
2.7 ± 2.3 respectively, with main impact on general activity, sleep and mood. Through-
out the 12-month study period, patients with persistent PHN presented lower scores 
on the physical (e.g. at 12 month: 39.7 ± 13.7) and mental (43.6 ± 11.3) component 
summaries of the 12-item short-form health survey (SF-12) than the patients without 
PHN, respectively 46.0 ± 10.6 and 47.8 ± 10.5. Moreover, univariate analysis found 
that among predictive factors at inclusion for PHN were a ZBPI score ≥5 (P < 0.001) 
and a low SF-12 physical component summary (P < 0.001). CONCLUSIONS: This 
large cohort study conﬁ rms the HZ and PHN impact on daily life and quality of life, 
in spite of prompt diagnosis and antiviral treatment.
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OBJECTIVES: HIV-infected patients demonstrate a health-related quality of life 
(HRQoL) lower than that of the general population. The goals of antiretroviral 
therapy (ART) include the improvement of HRQOL in addition to the reduction of 
symptoms, suppression of the virus, and enhancement of survival. The study evaluated 
HRQoL of HIV-infected patients at months 0 and 6 of receiving ART; and compared 
the HRQoL index of male and female participants. METHODS: The HRQoL of a 
cohort of 150 HIV-infected patients was evaluated at months 0 and 6 of receiving 
ART using SF-36 health survey form. Wilcoxon’s signed ranks test was used to 
compare the HRQoL index between two groups of data. All reported P values were 
2-sided, and P < 0.05 was used to determine statistical signiﬁ cance. RESULTS: The 
mean age of the 150 patients at initiation of antiretroviral treatment was 34.30 (95% 
CI, 32.96–35.64) years; and 59.3% were females. At 6 months follow-up, 118 
(78.7%) ART patients who met the 6th month medication reﬁ ll appointment were 
evaluated for HRQoL. Before commencing ART, the mean HRQoL of participants 
was 71.22 (95%CI, 68.00–74.44) which increased signiﬁ cantly to 90.83 (95%CI, 
88.49–93.17) at 6 months follow up on ART (P < 0.05). The change across all the 
HRQoL domains in the SF-36 instrument was also statistically signiﬁ cant (P < 0.05) 
except for the domains of role limitation due to emotional problems, social functioning 
and pain (p > 0.05). Difference in the HRQoL index of male and female gender at 
months 0 and 6 was not statistically signiﬁ cant (p > 0.05). CONCLUSIONS: There 
was a signiﬁ cant improvement in the mean HRQoL of the participants after 6 months 
of ART; the difference between HRQoL index of male and female participants was 
not signiﬁ cant. Routine evaluation of HRQoL in clinical practice is highly recom-
mended as long-term outcome may be different. 
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OBJECTIVES: Since the introduction of G-DRGs, hospitals have become increasingly 
concerned about impact of changes in clinical practice on hospital costs and revenue. 
We developed an algorithm to estimate expected G-DRG payment by drug, when 
length-of-stay (LOS) data from clinical trials are available. We compared results with 
a scenario where only median values by trial arm are available. METHODS: G-DRG 
attribution is driven by MV duration and intensive care severity score. From a Phase 
III trial comparing doripenem and imipenem (DORI-10), we determined nine catego-
ries of MV duration (ranges based on MV hours resulting in higher-paying G-DRGs). 
Using the Muenster Webgrouper, we obtained G-DRG weights when simultaneously 
varying MV duration and intensive care severity (15 levels) for four clinical proﬁ les. 
For the nine categories and by drug, we obtained percentage patients per group and 
median LOS by type of ward using. Per category, the appropriate G-DRG weight was 
selected based on: chosen proﬁ le, total MV duration, intensive care severity, and total 
LOS. Using distribution of patients by category derived from DORI-10, a weighted 
G-DRG was calculated for each arm, and multiplied by the 2010 base value to yield 
expected G-DRG payment. RESULTS: G-DRG revenue ranged from c2,578 to c8,575 
(across 4 scenarios) to c136,164 for MV ≥ 1800 hours. Using trial-based median LOS 
values, expected G-DRG revenue is c30,397 (all scenarios), with no difference in 
G-DRG revenue in both trial arms. When using the categories approach, expected 
revenue reduction when using doripenem instead of imipenem ranged from c2,084 to 
c2,451. CONCLUSIONS: A G-DRG revenue analysis helps to better understand net 
impact of introducing a new drug on a hospital’s budget. When LOS data (including 
MV) vary by drug and data from clinical studies are available, a classiﬁ cation 
approach enables more reﬁ ned G-DRG revenue estimates as opposed to using median 
values by drug.
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OBJECTIVES: Overuse of antibiotics has been focused for the public health and 
pharmaceutical expenditure in Korea. National Health Insurance introduced the anti-
biotics use monitoring program in 2002. This program includes a monitoring the 
antibiotics prescription rates of medical institutes, a feedback to prescribers, and a 
report to the public via website. This study aims to evaluate the impact of this program 
on the antibiotics prescription rates for the acute upper-respiratory infections (URI) 
in Korea. METHODS: We assessed the antibiotics prescription rates for the acute URI 
(J00-J06) of individual medical institutes from 2002 to 2008. Data was extracted from 
NHI outpatient’s claims database and the ﬁ rst quarter data of each year were selected 
to avoid seasonal variation. To evaluate the effect of program, we assumed the early 
change of prescription rate during 2002–2003 as a baseline, and compared it with 
every year variations of the prescription rate for 2004–2008. Generalized Estimation 
Equation (GEE) model was constructed to investigate the changes in antibiotics pre-
scription. RESULTS: Data included about 49 million claims from 13,211 clinics 
(94.5% of all acute URI claims and 70.5% of all clinics in 2008). Prescription rate 
declined from 72.8% to 55.1% during 2002–2008. The analysis showed that the 
antibiotics use monitoring program reduced 6.11% of antibiotics prescription rate per 
clinic annually (OR: 0.62, 95% CI: 0.61, 0.64, P < 0.0001). The reduced antibiotics 
prescription estimate was average 4.5 million a year. CONCLUSIONS: After monitor-
ing system introduced, the antibiotics prescription rates for acute URI patients have 
continuously decreased in the clinics.
